Drug intelligence / Profile preview

butylphthalide + sodium chloride

Development stage
Unknown
Lead developer
CSPC Pharmaceutical Group
Modality
Small Molecules
Administration
Intravenous
01

Overview

**Butylphthalide + sodium chloride** is an intravenous Chinese neuroprotective formulation marketed as **Enbipu** for improving neurological deficits in acute ischemic stroke. Each 100 mL infusion contains 25 mg of DL-3-n-butylphthalide and 0.9 g sodium chloride; sodium chloride functions as the vehicle rather than a second pharmacologically active drug. DL-3-n-butylphthalide is a lipophilic small molecule derived from a constituent originally identified in Chinese celery seed. Its clinical rationale is pleiotropic neuroprotection during cerebral ischemia, including improved ischemic-region microcirculation and energy metabolism, reduced oxidative stress and inflammatory signaling, inhibition of platelet aggregation and neuronal apoptosis, and support of neurological recovery. The usual regimen is intravenous administration of 100 mL twice daily for about 14 days.

Other names
butylphthalide and sodium chloride injectionbutylphthalide sodium chloride injectionDL-3-n-butylphthalide and sodium chloride injectionDL3-n-butylphthalide and sodium chloride injectionDL 3-n-butylphthalide and sodium chloride injectionDL-3-n-butylphthalide sodium chloride injectionDL3-n-butylphthalide sodium chloride injectionDL 3-n-butylphthalide sodium chloride injectionNBP sodium chloride injection
02

Targets

COX7C (Cytochrome c oxidase subunit 7C, mitochondrial)

Beyond the preview

Go deeper on butylphthalide + sodium chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on butylphthalide + sodium chloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call